Corbus Pharmaceuticals Holdings, Inc. (CRBP)

CRBP Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	14.39	17.67	25.68	86.45	31.75
Short-Term Investments	7.18	42.19	72.64	0	0
Cash & Cash Equivalents	21.58	59.87	98.32	86.45	31.75
Cash Growth	-63.96%	-39.11%	13.72%	172.31%	-23.95%
Other Current Assets	1.97	0.31	1.89	5.62	6.41
Total Current Assets	23.55	60.18	100.2	92.07	38.15
Property, Plant & Equipment	4.04	5.5	7	9.32	10.9
Other Long-Term Assets	0.69	0.63	0.52	0.9	0.08
Total Long-Term Assets	4.73	6.13	7.53	10.22	10.99
Total Assets	28.27	66.31	107.73	102.29	49.14
Accounts Payable	3.18	2.17	1.78	7.38	11.09
Current Debt	17.65	4.43	5	1.71	1.35
Other Current Liabilities	11.07	6.04	10.23	22.8	22.45
Total Current Liabilities	31.89	12.64	17.01	31.9	34.89
Long-Term Debt	3.24	20.66	21.59	25.12	8.1
Other Long-Term Liabilities	0.04	0.02	0.02	0	0
Total Long-Term Liabilities	3.28	20.68	21.61	25.12	8.1
Total Liabilities	35.18	33.32	38.62	57.02	42.98
Total Debt	20.88	25.09	26.59	26.84	9.45
Debt Growth	-16.76%	-5.65%	-0.92%	184.11%	2295.51%
Retained Earnings	-436.68	-392.08	-349.73	-304.09	-192.82
Comprehensive Income	-0	-0.13	-0.06	0	0
Shareholders' Equity	-6.9	32.99	69.11	45.27	6.16
Net Cash / Debt	0.69	34.78	71.73	59.62	22.3
Net Cash / Debt Growth	-98.01%	-51.51%	20.31%	167.30%	-46.07%
Net Cash Per Share	0.16	8.34	17.52	22.89	10.47
Working Capital	-8.35	47.54	83.2	60.18	3.27
Book Value Per Share	-1.60	7.91	16.88	17.38	2.89

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).